Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CELLCEPT vs AZASAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
Azathioprine is a purine analog that inhibits purine synthesis, thereby interfering with DNA and RNA synthesis. It is metabolized to 6-mercaptopurine, which inhibits T-cell activation and proliferation, leading to immunosuppression.
Prophylaxis of organ rejection in renal transplant recipients,Prophylaxis of organ rejection in cardiac transplant recipients,Prophylaxis of organ rejection in hepatic transplant recipients,Off-label: Treatment of lupus nephritis, autoimmune diseases, and other transplant indications
Renal transplant rejection prophylaxis,Rheumatoid arthritis,Off-label: inflammatory bowel disease (Crohn's disease, ulcerative colitis), lupus nephritis, autoimmune hepatitis, pemphigus vulgaris, myasthenia gravis, Behçet's disease, dermatomyositis, polymyositis
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
1-3 mg/kg/day orally once daily or divided twice daily; maximum dose 2.5 mg/kg/day for rheumatoid arthritis; usual dose 50-150 mg/day.
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
Terminal elimination half-life of azathioprine is approximately 4.5 hours (range 2–6 h), while its active metabolite 6-mercaptopurine has a half-life of 0.5–2 hours. Clinical context: Renal impairment prolongs half-life.
Mycophenolate mofetil is hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is primarily metabolized by glucuronidation via UDP-glucuronosyltransferases (UGT1A9 and UGT2B7) to MPA-glucuronide (MPAG), which is excreted in urine.
Metabolized via xanthine oxidase and thiopurine methyltransferase (TPMT) to active and inactive metabolites. Co-administration with allopurinol inhibits xanthine oxidase, requiring dose reduction of azathioprine.
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
Renal: 88% as 6-mercaptopurine and metabolites; biliary: <10%
97% bound to albumin. In renal impairment or hypoalbuminemia, free fraction increases.
30% bound to plasma proteins, primarily albumin.
Apparent volume of distribution of MPA is approximately 3.6 L/kg (range 1.5-5.0 L/kg), indicating extensive tissue distribution.
0.8–1.0 L/kg, indicating extensive distribution into tissues.
Oral bioavailability of mycophenolate mofetil is approximately 94% (converted to MPA). Intravenous: 100%.
Oral: 41–47% (azathioprine); 100% for IV administration.
For GFR 10-50 m L/min: maximum 2 g daily; for GFR <10 m L/min: maximum 1 g daily.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: 75% of normal dose; GFR <10 m L/min: 50% of normal dose.
No dosage adjustment required for hepatic impairment. No Child-Pugh based modifications are established.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
For ages 3 months to 18 years: 600 mg/m2 orally twice daily; maximum 2 g daily. Intravenous: same oral dose converted to IV.
2-3 mg/kg/day orally once daily; initial dose 1 mg/kg/day in divided doses; not recommended in children <1 year.
No specific dose adjustment, but start at lower end of dosing range due to age-related renal impairment. Monitor for adverse effects.
Start at low end of dosing range (50 mg once daily); monitor renal function and adjust accordingly.
Increased risk of pregnancy loss and congenital malformations; must avoid pregnancy during therapy. Use in women of childbearing potential only if contraception is used and pregnancy is excluded.
Chronic immunosuppression increases the risk of malignancy, particularly lymphoma and skin cancer. Patients should be monitored for neoplasia. The drug should be used only if potential benefits outweigh risks.
Increased susceptibility to infections (e.g., CMV, BK virus), lymphomas, and other malignancies; dose reduction in renal impairment; avoid use with azathioprine; monitor for neutropenia, GI bleeding, and progressive multifocal leukoencephalopathy.
Hematologic toxicity (leukopenia, thrombocytopenia, anemia) - monitor blood counts. Hepatotoxicity. Increased infection risk. Hypersensitivity reactions. TPMT deficiency increases toxicity risk. Monitor for pancreatitis, especially in Crohn's patients. Avoid live vaccines. Photosensitivity and skin cancer risk.
Hypersensitivity to mycophenolate mofetil or mycophenolic acid; women who are pregnant or planning pregnancy (unless no alternative); women of childbearing potential not using effective contraception.
Hypersensitivity to azathioprine or 6-mercaptopurine. Pregnancy (category D) unless potential benefit justifies risk. Lactation. Severe hepatic impairment. Myelosuppression or active infection. Concurrent use with allopurinol without dose adjustment.
Avoid taking with food high in fat or protein as it may reduce absorption. Grapefruit juice may decrease mycophenolate absorption; avoid concurrent consumption. No specific dietary restrictions besides maintaining consistent intake with meals.
No significant food interactions. May be taken with food to reduce gastrointestinal upset. Avoid concurrent use with raw or undercooked meats to reduce risk of infection due to immunosuppression.
First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube defects. Second and third trimester exposure may cause intrauterine growth restriction, preterm delivery, and neonatal immunosuppression. Mycophenolic acid is contraindicated in pregnancy unless no alternative treatment is available.
Azathioprine is FDA Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., atrial septal defect, limb defects) in case reports, but risk may be lower than with other immunosuppressants. Second and third trimesters: Risk of fetal growth restriction, preterm delivery, and neonatal immunosuppression. Avoid unless benefit outweighs risk.
M/P ratio is unknown. Mycophenolic acid is excreted into breast milk in small amounts; however, due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth delay, breastfeeding is not recommended during therapy.
Azathioprine is excreted into breast milk in small amounts; milk-to-plasma ratio approximately 0.1. Infant exposure is low, but theoretical risk of immunosuppression. Weigh benefits against risks; consider monitoring infant for leukopenia and infections.
No specific dose adjustments are established due to lack of pharmacokinetic data in pregnancy. Systemic exposure may be reduced due to increased plasma volume and metabolism; however, due to teratogenicity, use is contraindicated. If unavoidable, consider monitoring mycophenolic acid trough levels and adjust dose to maintain therapeutic range (1.0–3.5 mg/L), but safety is not established.
Increased clearance and reduced bioavailability during pregnancy may require dose increase to maintain therapeutic levels; monitor thiopurine metabolite levels (6-TGN, 6-MMP) and adjust accordingly. Often no change required if stable disease.
Mycophenolate mofetil (CELLCEPT) is a prodrug of mycophenolic acid, an inosine monophosphate dehydrogenase inhibitor. It is used for prophylaxis of organ rejection in renal, cardiac, and hepatic transplant recipients. Monitor for leukopenia, neutropenia, and infections. Dose adjustment required in renal impairment (GFR <25 m L/min). Avoid use in pregnancy (Pregnancy Category D). Contraindicated in hypersensitivity to mycophenolate. Intravenous administration should be over 2 hours. Monitor for GI bleeding and CMV infection.
Azasan (azathioprine) is a prodrug of 6-mercaptopurine. Screen for TPMT deficiency before initiation to avoid severe myelosuppression. Monitor CBC and liver function weekly for first month, then monthly. Corticosteroid-sparing agent in autoimmune conditions. Avoid live vaccines during therapy.
Take exactly as prescribed, with or without food. Do not crush or chew capsules.,Avoid sunlight and use sunscreen due to increased risk of skin cancer.,Report any signs of infection (fever, sore throat, unusual bleeding or bruising).,Use effective contraception during treatment and for 6 weeks after stopping if female of childbearing potential.,Do not breastfeed while taking this medication.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not change dose without consulting your doctor.,Report any signs of infection, unusual bruising/bleeding, or fatigue immediately.,Avoid exposure to individuals with infections; maintain good hand hygiene.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not receive live vaccines (e.g., MMR, varicella) while taking this medication.,Limit sun exposure; use sunscreen and protective clothing due to increased skin cancer risk.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CELLCEPT vs AZASAN, answered by our medical review team.
CELLCEPT is a Immunosuppressant that works by Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.. AZASAN is a Immunosuppressant that works by Azathioprine is a purine analog that inhibits purine synthesis, thereby interfering with DNA and RNA synthesis. It is metabolized to 6-mercaptopurine, which inhibits T-cell activation and proliferation, leading to immunosuppression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CELLCEPT and AZASAN depend on the specific clinical indication. These are both Immunosuppressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CELLCEPT is: Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.. The standard adult dose of AZASAN is: 1-3 mg/kg/day orally once daily or divided twice daily; maximum dose 2.5 mg/kg/day for rheumatoid arthritis; usual dose 50-150 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CELLCEPT and AZASAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CELLCEPT is classified as Category C. First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube de. AZASAN is classified as Category C. Azathioprine is FDA Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., atrial septal defect, limb defects) in case reports, but risk may be lower th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.